Ryvu Therapeutics SA Asset Resilience Ratio
Ryvu Therapeutics SA asset resilience ratio. Ryvu Therapeutics SA (RVU) has an Asset Resilience Ratio of 16.62% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See RVU defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ryvu Therapeutics SA (2011–2025)
Asset resilience ratio of Ryvu Therapeutics SA from 2011 to 2025. This chart shows how Ryvu Therapeutics SA's Asset Resilience Ratio has changed over time. Read RVU total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ryvu Therapeutics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see RVU total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł33.40 Million | 16.62% |
| Total Liquid Assets | zł33.40 Million | 16.62% |
Asset Resilience Insights
- Good Liquidity Position: Ryvu Therapeutics SA maintains a healthy 16.62% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Ryvu Therapeutics SA Industry Peers by Asset Resilience Ratio
Compare Ryvu Therapeutics SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 36.07% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
Ryvu Therapeutics SA Asset Resilience Ratio by Year (2011–2025)
Ryvu Therapeutics SA asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Ryvu Therapeutics SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 21.42% | zł48.07 Million ≈ $13.23 Million |
zł224.44 Million ≈ $61.77 Million |
+4.03pp |
| 2024-12-31 | 17.39% | zł65.86 Million ≈ $18.12 Million |
zł378.78 Million ≈ $104.24 Million |
-26.20pp |
| 2023-12-31 | 43.58% | zł175.73 Million ≈ $48.36 Million |
zł403.20 Million ≈ $110.97 Million |
+43.47pp |
| 2022-12-31 | 0.11% | zł528.00K ≈ $145.31K |
zł474.98 Million ≈ $130.72 Million |
-2.07pp |
| 2021-12-31 | 2.18% | zł4.99 Million ≈ $1.37 Million |
zł228.81 Million ≈ $62.97 Million |
-6.26pp |
| 2020-12-31 | 8.45% | zł24.97 Million ≈ $6.87 Million |
zł295.64 Million ≈ $81.36 Million |
+8.52pp |
| 2018-12-31 | -0.08% | zł-196.04K ≈ $-53.95K |
zł255.70 Million ≈ $70.37 Million |
+0.11pp |
| 2017-12-31 | -0.19% | zł-196.04K ≈ $-53.95K |
zł103.57 Million ≈ $28.50 Million |
-0.64pp |
| 2014-12-31 | 0.45% | zł120.00K ≈ $33.03K |
zł26.80 Million ≈ $7.38 Million |
-0.22pp |
| 2013-12-31 | 0.67% | zł120.00K ≈ $33.03K |
zł17.98 Million ≈ $4.95 Million |
+1.72pp |
| 2012-12-31 | -1.06% | zł-162.04K ≈ $-44.60K |
zł15.35 Million ≈ $4.22 Million |
-0.50pp |
| 2011-12-31 | -0.56% | zł-98.08K ≈ $-26.99K |
zł17.50 Million ≈ $4.82 Million |
-- |
About Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myel… Read more